Emovi Selected by the Consulate General of Canada
in Boston, United States, to Join the
2020 Cohort for the Canadian Technology Accelerator
Montreal, Quebec (April, 2020) – Emovi, Inc., a global medical device company, announced today that they were selected to join the Canadian Technology Accelerator (CTA) in Boston, MA. Emovi was selected with 10 other companies to participate in the 2020 cohort. During the six-month residency, which includes office space at the Cambridge Innovation Center (CIC) in Kendall Square in Cambridge, Massachusetts, Emovi will work with the Trade Commissioners to scale their presence in the New England Market.
The Canadian Technology Accelerator in Boston (CTA Boston) is an award-winning incubator program that drives growth for small and medium-sized Canadian companies. Operated by the Consulate General of Canada in Boston, the program has assisted over 100 Canadian companies since its founding in 2013 with its unique business acceleration services that help companies commercialize or scale their business in the US market. This year’s cohort is comprised of eleven Canadian companies ranging from technology to life sciences.
“The CTA – Boston program is highly competitive, and I am honored that Emovi has been selected to participate in the 2020 cohort,” said Michelle Laflamme, Emovi CEO. “Knee pain affects one-third of Americans at some point in their life; this program provides an exclusive opportunity for Emovi to tap into the Boston ecosystem and continue to grow our presence in the United States.”
Emovi, Inc. has developed the KneeKG, the first in-clinic device that enables doctors to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. In contrast to the information provided by X-ray and magnetic resonance imaging (MRI) while the patient is in static position, KneeKG quickly identifies the functional motion of impaired knee(s) to allow healthcare professionals to determine the most appropriate care pathway to restore optimal knee functionKneeKG can pinpoint functional deficits linked to knee osteoarthritis, ligament injuries, instabilities, and anterior knee pain. By providing additionalinformation to doctors with a higher correlation to symptoms, the KneeKG allows doctors to significantly improve patients’ quality of life, pain, and functional limitations.
Continued Laflamme, “We look forward to working with the trade commissioners in Boston with their expertise and on-the-ground intelligence and connections in order to bring the KneeKG to more clinicians and improve knee care for patients.”
About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de Technologie supérieure (ÉTS), and TELUQ, Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive worldwide license to commercialize KneeKG. http://emovi.ca
KneeKG is the first device that enables doctors to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the dynamic function of impaired knees allowing healthcare professionals to determine the most strategic treatment plan to restore the knee. By providing doctors with technical information that has a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs, the KneeKG allows healthcare professionals to significantly improve patients’ quality of life while reducing pain and functional limitations. KneeKG is FDA 510(k) cleared, Health Canada Lisenced and CE Marked.